Allume from Quintiles Helps Biopharma Navigate Market Entry

RESEARCH TRIANGLE PARK, NC – July 10, 2012 – Quintiles today introduced Allume^™, a comprehensive go-to-market service to help biopharmaceutical companies efficiently launch new products and shorten timelines to peak sales, while retaining strategic and corporate control of their assets.  Allume^™ simplifies and organizes the complex and resource-intensive launch planning process; provides unique data-driven insights from 15 years of market entry experience across the globe; and taps Quintiles’ local market and therapeutic category expertise.

“Biopharma companies are looking for new ways to optimize product value, expedite market access, mitigate commercialization risk, yet retain asset value, while reaching patients across diverse geographic regions,” said Dean Summerfield, Vice President, Consulting, Quintiles. “To maximize value, they need to start planning product launch early in the drug development process, especially when preparing to enter new geographic markets. Through Allume^™ Quintiles provides the strategic thinking, local market knowledge, deep therapeutic insight and market access approaches to help our customers map and navigate a pathway to commercial success.”

A unique combination of Consulting, Clinical and Commercial expertise, paired with state-of-the-art software, Allume^™ incorporates Quintiles’ years of biopharma product launch experience into flexible, seamless support that complements in-house capabilities. It can be fully customized to each company and product to help identify key market challenges, fast-track launch rollout and improve efficiency in resource management. This cost-effective solution allows companies to benefit from Quintiles’ product lifecycle expertise rather than assume the financial risk of creating their own infrastructure to support launch planning early in the commercialization process.